Evidence map›Paper›PMID 42020362›Full record

ReviewCell death & disease2026

c-FLIP as a master regulator of immune homeostasis and disease mechanisms.

Eliana Urbini, Annalisa Adamo, Yushu Hu, Luca Giacobazzi, Silvia Dusi, Francesco De Sanctis, Carmine Carbone, Davide Gibellini, Sara Pilotto, Vincenzo Corbo and 3 more

Abstract readReview
In one paragraph

Review in Cell death & disease, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Eliana Urbini *Immunology Section, Department of Medicine, University of Verona and Verona University Hospital Trust Verona, Verona, Italy.
Annalisa Adamo *Immunology Section, Department of Medicine, University of Verona and Verona University Hospital Trust Verona, Verona, Italy.
Yushu Hu *Immunology Section, Department of Medicine, University of Verona and Verona University Hospital Trust Verona, Verona, Italy.
Luca GiacobazziImmunology Section, Department of Medicine, University of Verona and Verona University Hospital Trust Verona, Verona, Italy.
Silvia DusiImmunology Section, Department of Medicine, University of Verona and Verona University Hospital Trust Verona, Verona, Italy.
Francesco De SanctisImmunology Section, Department of Medicine, University of Verona and Verona University Hospital Trust Verona, Verona, Italy.
Carmine CarboneDepartment of Medical and Surgical Sciences, Medical Oncology, Fondazione Policlinico Universitario "Agostino Gemelli" IRCCS, Rome, Italy.ORCID http://orcid.org/0000-0001-5168-747X
Davide GibelliniMicrobiology Section, Department of Diagnostic and Public Health, University of Verona and Verona University Hospital Trust, Verona, Italy.
Sara PilottoSection of Innovation Biomedicine - Oncology Area, Department of Engineering for Innovation Medicine (DIMI), University of Verona and Verona University Hospital Trust, Verona, Italy.
Vincenzo CorboDepartment of Engineering for Innovation Medicine, University of Verona, Verona, Italy.ORCID http://orcid.org/0000-0002-6340-8009
Vincenzo BronteImmunology Section, Department of Medicine, University of Verona and Verona University Hospital Trust Verona, Verona, Italy.ORCID http://orcid.org/0000-0002-3741-5141
Fulvia VascottoTRON, Translational Oncology at the University Medical Center of the Johannes Gutenberg University Mainz gGmbH, Mainz, Germany.
Stefano UgelImmunology Section, Department of Medicine, University of Verona and Verona University Hospital Trust Verona, Verona, Italy. stefano.ugel@univr.it.ORCID http://orcid.org/0000-0002-6639-7608

Funding

Associazione Italiana per la Ricerca sul Cancro (Italian Association for Cancer Research) 21509Associazione Italiana per la Ricerca sul Cancro (Italian Association for Cancer Research) 28730Associazione Italiana per la Ricerca sul Cancro (Italian Association for Cancer Research) 32017Associazione Italiana Sclerosi Multipla (Italian Multiple Sclerosis Society) B37G25000050007
6 · The paper itself

Abstract

Cellular FLICE (FADD-like IL-1β-converting enzyme)-inhibitory protein (c-FLIP) was discovered more than three decades ago and has since emerged as a multifunctional regulator of cell fate. Initially identified through its homology with viral FLIP (v-FLIP) proteins and its ability to inhibit death receptor-induced apoptosis, c-FLIP is now recognized as a pivotal molecule at the crossroads of apoptosis, necroptosis, autophagy, and inflammation. Beyond its classical anti-apoptotic role, c-FLIP modulates key signaling pathways, including nuclear factor-κB (NF-κB), mitogen-activated protein kinase (MAPK), and Wnt/β-catenin, thereby influencing immune cell activation, differentiation, and tolerance. In immune cells, c-FLIP expression determines susceptibility to death receptor signaling and fine-tunes inflammatory responses, contributing to the balance between immune activation and suppression. Aberrant c-FLIP regulation has been implicated in cancer, autoimmunity, and chronic inflammatory diseases, positioning it as both a biomarker and a potential therapeutic target. This review summarizes current understanding of c-FLIP structure, isoforms, and regulation; delineates its roles in apoptosis and non-apoptotic pathways; and discusses its critical function in orchestrating immune homeostasis and disease pathogenesis. By integrating mechanistic and translational perspectives, we highlight c-FLIP as a central hub that links cell death, immunity, and therapeutic opportunities.

Indexed as

CASP8 and FADD-Like Apoptosis Regulating ProteinHomeostasisAnimalsApoptosisHumansInflammationSignal TransductionCASP8 and FADD-Like Apoptosis Regulating Protein

Identifiers

PMID42020362
PMCPMC13233873

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.